Your Article Summary
See Latest ArticlesPhysiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis
Critical Reviews in Oncology/Hematology, 06/11/09
Tubiana-Hulin M et al. - Dental procedures could worsen the risk of ONJ, and indications must be well evaluated. When an ONJ occurs, the management should be adapted according to its extent. Thereby, a customization of BP therapy should be applied taking into account the aggressiveness of the underlying disease.
Related Articles
Extended Use of Intravenous Bisphosphonate Therapy for the Prevention of Skeletal Complications in Patients with Cancer
Cancer Investigation, 11/16/09
Relevance Score: 68%
Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/10/09
Relevance Score: 68%
Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy
The Journal of Urology, 10/16/09
Relevance Score: 67%
Bisphosphonates in breast cancer: teaching an old dog new tricks
Current Opinion in Oncology, 10/12/09
Relevance Score: 66%
The Effect of Prior Bisphosphonate Therapy on the Subsequent BMD and Bone Turnover Response to Strontium Ranelate
Journal of Bone and Mineral Research, 10/02/09
Relevance Score: 66%
Today in OMF Pathology...keeping you current
Receive free subspecialty "5-minute updates" via email
Ameloblastoma of the jaws: A critical reappraisal based on a 40-years single institution experience
Oral Oncology , 12/15/09
Diagnostic reliability of FNAC for salivary gland swellings: A comparative study
Diagnostic Cytopathology, 12/15/09
Recessive dystrophic epidermolysis bullosa—oral rehabilitation using stereolithography and immediate endosseous implants
Special Care in Dentistry, 12/15/09